BMO Capital Markets Cuts Spark Therapeutics (ONCE) Price Target to $48.00

Spark Therapeutics (NASDAQ:ONCE) had its price target lowered by BMO Capital Markets to $48.00 in a research report report published on Wednesday, The Fly reports. BMO Capital Markets currently has a market perform rating on the biotechnology company’s stock.

A number of other research firms have also commented on ONCE. Royal Bank of Canada lowered Spark Therapeutics from an outperform rating to a sector perform rating and set a $100.00 price objective on the stock. in a research note on Thursday, July 19th. Cantor Fitzgerald set a $103.00 price objective on Spark Therapeutics and gave the stock a buy rating in a research note on Monday, July 16th. ValuEngine lowered Spark Therapeutics from a strong-buy rating to a buy rating in a research note on Tuesday, July 24th. Raymond James set a $82.00 price objective on Spark Therapeutics and gave the stock a buy rating in a research note on Wednesday, August 8th. Finally, SunTrust Banks lowered their price objective on Spark Therapeutics to $61.00 and set a buy rating on the stock in a research note on Wednesday, August 8th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. The company has an average rating of Hold and an average target price of $68.52.

Shares of NASDAQ ONCE traded down $3.24 during trading hours on Wednesday, reaching $42.76. 666,734 shares of the stock were exchanged, compared to its average volume of 567,755. The firm has a market cap of $1.71 billion, a P/E ratio of -5.60 and a beta of 2.27. The company has a current ratio of 10.71, a quick ratio of 18.14 and a debt-to-equity ratio of 0.09. Spark Therapeutics has a 52 week low of $39.01 and a 52 week high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.04) by ($0.22). Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $27.44 million. During the same quarter last year, the business earned ($1.90) EPS. Spark Therapeutics’s revenue was up 463.2% on a year-over-year basis. Analysts forecast that Spark Therapeutics will post -1.44 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Spark Therapeutics in the 3rd quarter valued at $122,000. Bank of Montreal Can increased its stake in shares of Spark Therapeutics by 1,045.4% in the 3rd quarter. Bank of Montreal Can now owns 3,253 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 2,969 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Spark Therapeutics in the 2nd quarter valued at $203,000. Smith Asset Management Group LP increased its stake in shares of Spark Therapeutics by 39.6% in the 3rd quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock valued at $215,000 after purchasing an additional 1,120 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Spark Therapeutics by 100.0% in the 3rd quarter. SG Americas Securities LLC now owns 4,493 shares of the biotechnology company’s stock valued at $245,000 after purchasing an additional 2,246 shares during the last quarter.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Further Reading: Understanding Market Liquidity

The Fly

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply